Join us for Medical Cannabis Week 2020

2 mins read

Since 2018, Business of Cannabis has produced Medical Cannabis Week to surface and celebrate insights and innovations from patients, practitioners and the industry. While a full week, in-person Medical Cannabis Week event was not possible in May 2020, we are moving ahead with a weeklong, virtual Medical Cannabis Week in November 2020.

Monday, November 16 – Day 1 | Patients + Practitioners

To start off Medical Cannabis Week, we will focus on patients and practitioners – including access to and efficacy of medical cannabis. Day 1 highlights include a conversation with Dr. Carolina Landolt of the Summertree Medical Clinic and the Science Advisory Committee of MediPharm Labs.

Tuesday, November 17 – Day 2 | Innovation + Research

This day of Medical Cannabis Week, will focus on innovation and research happening in the medical cannabis space, especially as it relates to Canada. Day 2 highlights include a presentation from Dr. Chris Talpas the Vice President, Quality and Scientific Affairs at MediPharm Labs. 

Wednesday, November 18 – Day 3 | Advocacy

As the medical cannabis program in Canada develops, understanding and supporting the patients – without whom there would be no industry – is critical. Along with Medical Cannabis Canada, this program will look at challenges for patients and the advocacy efforts to support them including a panel of patients sharing their experiences with the medical cannabis program in Canada.

Friday, November 20 – Day 5 | Cannabis + Sport

On the final day of Medical Cannabis Week, we will focus on the intersection of cannabis and sport – a topic gaining increased focus from current and retired athletes, doctors and trainers and policy makers and governing bodies. Day 5 will be anchored by a conversation with current and retired athletes as well as medical professionals and advocacy groups serving athletes. Day 5 is presented in conjunction with Athletes for Care.

Previous Story

Innovating in the Medical Cannabis Space at Blake, Cassels & Graydon LLP

Next Story

Understanding the medical cannabis patient perspective in Canada

0 $0.00